Skip to main content
. Author manuscript; available in PMC: 2018 Jan 17.
Published in final edited form as: Cell Rep. 2017 Dec 26;21(13):3672–3680. doi: 10.1016/j.celrep.2017.12.014

Figure 2. Soluble Antigen Treatment Reduces the Number of Immunodominant B Cells in GCs and Favors the Expansion of Subdominant Cells.

Figure 2

(A) Schematic outline of experimental approach for (A–F). Mice were immunized i.p. with 10 μg of NP4-OVA in precipitated alum, and then treated with soluble NP-Ficoll or PBS on days 6 through 8. Spleens were dissected 9, 12, or 21 days after immunization.

(B and C) Representative plots of GC frequency (B220+, CD4−, GL7+, CD38lo) (B) and quantification (C).

(D) Representative gating for antigen-specific GC B cells (B220+, GL7+, CD4−, CD38lo, and OVA+/NP−, or OVA−/NP+).

(E and F) Quantification of NP-specific (E) and OVA-specific (F) GC B cell frequency and cell number.

(G and H) Mice were immunized i.p. with 1 μg of CRM-OVA, and then treated with soluble OVA or PBS on day 7. Spleens were dissected 12 days after immunization. Representative plots of antigen-specific GC B cells (G) and quantification of CRM+ cells (H).

Cell counts are normalized to 106 lymphocytes. Bars represent mean; NS, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, Welch’s t test. See also Figure S2.